TECHWIRE 30
(CIX: WRAL30)  1,074.75    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: Apple)  107.72    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: QUINTILES)  71.90    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(OP: BASF SE)  78.24    (0 %)  Updated: 05:20 PM EDT, Sep 01 2015
(NQ: BioCryst)  11.22    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: BioDelivery)  6.44    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: CEMP)  33.43    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: Cisco)  25.12    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: Cree)  26.07    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: DARA)  0.86    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: EMC)  24.01    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NQ: Extreme Networks)  2.93    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: Facebook)  87.23    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: GLAXOSMITHKLINE)  39.47    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NQ: Google)  597.79    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: IBM)  142.68    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NY: LH)  115.75    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(OP: Lenovo Group)  15.65    (0 %)  Updated: 05:20 PM EDT, Sep 01 2015
(NY: MRK)  52.53    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NQ: Microsoft)  41.82    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: NetApp)  30.96    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: NOVARTIS AG)  94.68    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(OP: Novozymes A/S)  43.08    (0 %)  Updated: 05:20 PM EDT, Sep 01 2015
(NY: Pfizer)  31.36    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NQ: Pozen)  8.59    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NY: Red Hat)  70.04    (0 %)  Updated: 06:40 PM EDT, Sep 01 2015
(NQ: BBRY)  7.34    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  10.96    (0 %)  Updated: 08:10 PM EDT, Sep 01 2015

Posts tagged “BDSI”

Updated August 13

Premium Lock With FDA approval in hand, Raleigh drug firm BDSI looks for partners

BioDelivery Sciences has received approval from the Food and Drug Administration for a new formulation of its treatment targeting breakthrough cancer pain. Now the company wants to find a partner to commercialize it.

How BDSI technology works How BDSI technology works

Updated August 13

Wilmington network adds crowdfunding; BDSI hires Salix execs; Facebook dumps intern; $200M for Vox; Rdio adds 500 stations

Bulldog Bulletin In today's wrapup of technology and life science news: Wilmington-based Connected Investors adds crowdfunding for real estate; Raleigh-based BDSI hires two Salix execs; Facebook dumps an intern turned critic; Vox lands $200 million from NBC Universal; and Rdio adds 500 stations.

Updated June 2

Premium Lock BDSI borrows $21M; Intel's $17B buy; BlackBerry, Typo settle; Avago acquires Broadcom; Google's free storage

Bulldog In today's Bulldog wrapup of technology and life science news: Raleigh-based BioDeliverySciences raises $21 million in new debt; Intel to acquire chip designer Altera; BlackBerry settles with Ryan Seacrist's Typo; Avago pays $37B for Broadcom; and Google offers free storage for photos, videos.

Updated March 31

Premium Lock Praise for SciQuest; BDSI shares tumble; Scynexis loss; Amazon's referrals; PlayStation gets Spotify

Bulldog In today's Bulldog wrapup of technology and life science news: SciQuest receives good news from a research firm; BDSI stop drops 24 percent on drug trial news; Scynexis posts a $4.2 million loss; Amazon launches its own referral service; and the PlayStation network embraces Spotify.

February 23

Premium Lock FDA news means $10M payday for BioDelivery Sciences

Raleigh-based BioDelivery Sciences will receive a $10 million milestone payment from partner Endo Pharmaceuticals now that the FDA has accepted a new drug application for the severe pain reliever system known as Belbuca.

How BDSI technology works How BDSI technology works

Updated January 28

Premium Lock Apple's blowout quarter; ChannelAdvisor adds Jet; AT&T revenue up 4%; BDSI to relaunch pain drug; Snapchat's media deal

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Apple reports a blowout quarter; ChannelAdvisor adds new service; AT&T grows revenue but books $4B loss; BDSI to relaunch pain treatment; Sanpchat to show media news.

June 9, 2014

Premium Lock BioDelivery Sciences could soar with FDA approval of Bunavail

More than two million people suffer from opioid dependence in the United States. BioDelivery's FDA approval for Bunavail may open up tremendous revenue streams for the Raleigh-based drug company.

How BDSI technology works How BDSI technology works

March 27, 2014

Premium Lock BioDelivery Sciences picks Quintiles to help launch proposed drug

Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.

How BDSI technology works How BDSI technology works

Updated February 10, 2014

Premium Lock Pain drug firm BioDelivery Sciences raising $60M in stock sale

BDSI Capitalizing on news that its chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, BioDelivery Sciences International is raising $60 million to finance commercialization efforts.

January 24, 2014

Premium Lock Pain drug from BDSI shows positive trial results, triggers $10M milestone

BDSI Chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, and securing trial data for further analysis has triggered a $10 million milestone to BioDelivery Sciences International.

December 3, 2013

Premium Lock BDSI hires key sales executive ahead of expected 2014 drug launch

BDSI's drug pipeline BioDelivery Sciences International's opioid dependence treatment Bunavail faces an FDA decision date of June 7 and the Raleigh company is getting ready to go to market if it secures regulatory approval.

Updated December 2, 2013

Premium Lock BioDelivery Sciences targets more tests for neuropathy treatment after 'positive' FDA meeting

Diabetes BioDelivery Sciences invested a mix of stock and cash that could total nearly $40 million if a proposed gel to treat diabetic neuropathy pain wins FDA approval, and the company says it will proceed with further tests after a "positive" meeting with regulators.

Updated October 21, 2013

Premium Lock BioDelivery Sciences names new chief financial officer

BDSI The Raleigh-based firm says its current CFO Jim McNulty will assume a new role as senior vice president for finance and treasurer.

October 9, 2013

Premium Lock BioDelivery Sciences' opioid treatment could win FDA approval in '14

The Raleigh-based drug delivery technology firm projects sales of up to $250 million if the opioid dependence treatment wins FDA approval next year.

How BDSI technology works How BDSI technology works

August 15, 2013

Premium Lock BDSI makes drug pipeline progress but reports $13.1M 2Q loss

BDSI BDSI swings to a $13.1 million loss in the second quarter, a change that reflects the $15 million milestone payment the company recorded in the second quarter of 2012.

August 1, 2013

Premium Lock Opioid dependence treatment from BDSI filed for FDA approval

BDSI's drug pipeline With Bunavail, BDSI aims to secure FDA approval on the first opioid dependence treatment that delivers abuse deterrents through the lining of the cheek.

July 29, 2013

Premium Lock BioDelivery Sciences' pain killer wins OK in Taiwan

BDSI The approval triggers a $300,000 milestone payment and future royalties from BDSI's partner in the island nation.

July 12, 2013

Premium Lock Drug delivery and more: BDSI flashes potential of revived drug pipeline

BioDelivery Sciences International's current pipeline reflects a shift in direction and a effort to stretch beyond the drug-delivery technology that was the initial focus for the company. Learn more about BDSI's strategy.

BDSI's drug pipeline BDSI's drug pipeline

July 8, 2013

Premium Lock BDSI lands $20M loan to support drug application, clinical trials

BDSI The $20 million loan shores up BDSI's finances as it prepares a new drug application for Bunavail and finishes phase III trials on a chronic pain drug candidate.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith